Matrix protein of vesicular stomatitis virus: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation

2013 ◽  
Vol 20 (3) ◽  
pp. 178-185 ◽  
Author(s):  
Y Zhou ◽  
F Wen ◽  
P Zhang ◽  
R Tang ◽  
Q Li
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Vesicular Stomatitis Virus ◽  
Matrix Protein ◽  
Potent Inhibitor ◽  
Malignant Ascites ◽  
Vascular Endothelial ◽  
Ascites Formation ◽  
Vesicular Stomatitis ◽  
Endothelial Growth Factor

Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites

1999 ◽  
Vol 6 (4) ◽  
pp. 373-378 ◽  
Author(s):  
Brian K. Zebrowski ◽  
Wenbiao Liu ◽  
Karen Ramirez ◽  
Yoshito Akagi ◽  
Gordon B. Mills ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Malignant Ascites ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

scholarly journals Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application

2012 ◽  
Vol 2012 ◽  
pp. 1-14 ◽  
Author(s):  
Afshin Amini ◽  
Samar Masoumi Moghaddam ◽  
David L. Morris ◽  
Mohammad H. Pourgholami
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Treatment Options ◽  
Malignant Ascites ◽  
Vascular Endothelial ◽  
Chemotherapeutic Drugs ◽  
Gynecologic Malignancy ◽  
Preclinical And Clinical Studies ◽  
Endothelial Growth Factor

Despite recent advances in the management of ovarian cancer, it remains the most lethal gynecologic malignancy. Vascular endothelial growth factor (VEGF) has been shown to play a pivotal role in the progression of ovarian cancer leading to the eventual development of malignant ascites. On this basis, agents rendering VEGF ineffective by neutralizing VEGF (bevacizumab), blocking its receptors (aflibercept), or interfering with the postreceptor signaling pathways (sunitinib) provide us with the rational treatment options. These agents are generally used in combination with the standard chemotherapeutic drugs. Here, we discuss the basis of and the logic behind the use of these agents in the treatment of epithelial ovarian cancer, as well as their evaluation in different preclinical and clinical studies.

Sign in / Sign up

Export Citation Format

Share Document